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3. Counterfeiting and public health
Duncan Matthews
1. INTRODUCTION
In the debate about counterfeiting and public health there is a tendency 
to conflate three distinct issues: first, counterfeit goods that infringe trade-
marks; second, medicines suspected of infringing patents; and, third, falsi-
fied medicines which contain the wrong or insufficient active ingredients.1
2. COUNTERFEITING
Counterfeiting is a term with a very specific meaning in intellectual prop-
erty law. It describes the theft of brand owners’ intellectual property, 
namely a trademark violation.2 This very specific meaning of the term is 
set out in the World Trade Organization (WTO) Agreement on Trade-
Related Aspects of Intellectual Property Rights (TRIPS Agreement), 
which defines counterfeiting as use of a trademark or mark similar to a 
trademark without the permission of the rights holder.
Specifically, the TRIPS Agreement defines ‘counterfeit goods’ in foot-
note 14 of Article 51 as:
any goods, including packaging, bearing without authorisation a trademark 
which is identical to the trademark validly registered in respect of such goods, 
or which cannot be distinguished in its essential aspects from such a trademark, 
and which thereby infringes the rights of the owner of the trademark in ques-
tion under the law of the country of importation.3
 1 See also South Centre/Center for International Environmental Law (CIEL) 
(2008), ‘The International Medical Products Anti-Counterfeiting Taskforce 
(IMPACT): Is the WHO on the Right Track?’, Intellectual Property Quarterly 
Update, Third Quarter, 1.
 2 See also Clift, C. (2010), ‘Counterfeit Medicines: Health and Harm’, The 
World Today, 66 (12): http://www.chathamhouse.org/publications/twt/archive/
view/169913 (accessed 12 March 2012). 
 3 Article 51, footnote 14, of the TRIPS Agreement: http://www.wto.org/
english/tratop_e/trips_e/t_agm4_e.htm#Footnote14 (accessed on 13 March 2012).
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In the context of pharmaceutical products, the World Health Organization 
(WHO) uses a similar definition to describe a counterfeit medicine as one 
that is ‘deliberately and fraudulently mislabelled with respect to identity 
and/or source.’4 Particular countries also define in different ways what is to 
be understood by counterfeiting. In the United States, it is directly related 
to trademark violations.5 Other countries focus instead on the active phar-
maceutical ingredients (APIs) contained in medicinal products.6
In the EU, Directorate General Taxation and Customs Union 
(TAXUD) of the European Commission has reported that ‘[c]ounterfeit-
ing is a growing and increasingly dangerous phenomenon’ and that ‘[c]
ounterfeited . . . articles threaten the health and safety of EU citizens, their 
jobs, Community competitiveness, trade, and investment in research and 
innovation’.7 In 2010, EU Customs seized more than 103 million counter-
feit and pirated goods and handled more anti-counterfeiting cases than 
ever before. A total of more than 79 000 cases were dealt with in 2010, 
up nearly 84 per cent from 2009.8 For TAXUD, the increasing use of the 
Internet to sell medicines classified as counterfeit and the fact that the high 
 4 WHO (1992), Counterfeit Drugs: Report of a Joint WHO/IFPMA Workshop, 
WHO/DMP/CFD/92 1–3 April, Geneva. This definition was incorporated into the 
1999 WHO Guidelines for the Development of Measures to Combat Counterfeit 
Medicines, WHO/EDM/QSM/99, and is also included in the WHO Quality 
Assurance of Medicines Terminology Database of 8 December 2011: http://www.
who.int/medicines/services/expertcommittees/pharmprep/20111208_Q ASterm ino l 
ogyDB.pdf (accessed 13 March 2012).
 5 United States Federal Food Drug and Cosmetic Act, SEC. 201, Title 21 
United States Code 321, G(2):
The term ‘counterfeit drug’ means a drug which, or the container or labelling 
of which, without authorization, bears the trademark, trade name, or other 
identifying mark, imprint, or device, or any likeness thereof, of a drug manu-
facturer, processor, packer, or distributor other than the person or persons who 
in fact manufactured, processed, packed or distributed such drug and which 
thereby falsely purports or is represented to be the product of, or to have been 
packed or distributed by, such other drug manufacturer, processor, packer or 
distributor. 
 6 South Centre/CIEL, supra n. 1, 7.
 7 Directorate General for Taxation and Customs Union of the European 
Commission (2010), Customs Controls – A serious problem for everyone: http://
ec.europa.eu/taxation_customs/customs/customs_controls/counterfeit_piracy/co m 
bating/index_en.htm.
 8 European Commission, Taxation and Customs Union, Report on EU 
customs enforcement of intellectual property rights: Results at the EU border – 
2010, p. 11: http://ec.europa.eu/taxation_customs/resources/documents/customs/
customs_controls/counterfeit_piracy/statistics/statistics_2010.pdf (accessed 13 
March 2012). 
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quality of such goods often makes identification impossible without tech-
nical expertise increases the challenge customs face.
However, there are concerns that statements about levels of counter-
feiting are based either on inaccurate use of the term ‘counterfeit’, or on 
customs seizures, with the actual quantities of infringing goods in free cir-
culation in any particular market largely unknown, or on estimated losses 
derived from industry surveys. Industry estimates of levels of counterfeit 
are considered to exhibit an upward bias, with the difficulty in estimating 
levels of actual counterfeiting and piracy exacerbated by the failure to use 
the definition of the terms as set down in the TRIPS Agreement.9
The high levels reported in most industry-based surveys has been 
identified as a problematic aspect of the expert reports used as the basis 
of the 2007 Organization for Economic Co-operation and Development 
(OECD) report on counterfeiting.10 The OECD report has also been criti-
cized for framing the problem of intellectual property-related crime exclu-
sively through the lens of ‘counterfeiting’ and lost corporate revenue, in 
doing so overlooking the social costs of intellectual property enforcement 
that restricts access, creates barriers to follow-on innovation, and encour-
ages anti-competitive business practices.11
A key assumption in most estimates is that the sale of counterfeit goods 
displaces legitimate sales, regardless of how the price of goods may be 
affected by stronger intellectual property protection. An issue of concern 
for the OECD has been the extent to which assumptions can be made 
about the degree of substitutability between infringing and legitimate 
items.12 Likewise, the methodology used in the surveys to calculate levels 
of intellectual property rights infringement in third countries has been 
criticized on grounds that it is largely based on the industry’s subjective 
opinion.13 For developing countries there is a risk that the promotion of 
increased emphasis on intellectual property rights enforcement, based on 
imperatives driven by industry figures, increases the need for the allocation 
 9 Tekeste Biadgleng, E. and Munoz Tellez, V. (2008), The Changing Structure 
and Governance of Intellectual Property Enforcement, Geneva: South Centre, p. 20.
10 Organization for Economic Co-operation and Development (OECD) 
(2007), The Economic Impact of Counterfeiting and Piracy, DSTI/IND(2007)9/
PART4/REV1.
11 Shaw, A. (2008), ‘The Problem with the Anti-Counterfeiting Trade 
Agreement (and what to do about it)’, KEStudies, 2, 1–9, at 5.
12 Olsen, K. (2005), Counterfeit and Piracy: Measurement Issues, Background 
Report for the WIPO/OECD Expert Meeting on Measurement and Statistical Issues, 
Geneva, 17–18 October, OECD: http://www.oecd.org/dataoecd/42/44/35651123.
pdf (accessed on 13 March 2012).
13 Tekeste Biadgleng, and Munoz Tellez, supra n. 8, p. 20.
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of additional human and financial resources and limits the scope for utiliz-
ing TRIPS flexibilities in favour of public health. There is also the problem 
that systematic research on the health and safety effects of counterfeit 
products is almost non-existent.14
Given the very specific meaning of counterfeiting adopted by the TRIPS 
Agreement and the WHO, there are concerns that use of this term to 
describe medicines that are generic drugs sold legitimately on the market 
will create confusion and risk prioritizing the enforcement of intellectual 
property rights over public health.15 The counterfeiting of high-price 
medicines is a growing illegal business. Generic drugs that do not infringe 
trademarks are not counterfeit goods. Unauthorized uses of a product 
that are allowed by law, such as products made under legitimate limita-
tions and exceptions to patents, or generic medicines that are off-patent 
or legitimately licensed under voluntary or non-voluntary licences, are 
not counterfeit products.16 So, not all infringements of patents or other 
intellectual property rights can be described as counterfeits, and often the 
issue of what constitutes infringement is itself a matter of controversy, 
with issues of patent validity quite different from trademark law, where the 
relationship between rights and exceptions to rights is complex.17
Consequently, it is important to differentiate between counterfeiting and 
the importation of legitimate products at a lower price, as ‘grey market’ 
parallel traded goods that are acquired legitimately in one market, and 
resold legally under the exhaustion of rights doctrine in another market.18 
The tendency to conflate the two issues has the effect of stigmatizing the 
practice and ignoring the potential benefits of parallel trade if the view 
is taken that restrictions on parallel trade can lead to anti-competitive 
behaviour, and by facilitating market segmentation and price discrimina-
tion, resulting in higher prices for consumers in markets that have a lack 
of competition.
14 Olsen, supra n. 12.
15 Mara, K. (2010), ‘Counterfeit Medicines in WTO Dispute Process, Heating 
up at WTO’, Intellectual Property Watch, 12 May 2010: http://www.ip-watch.org/
weblog/2010/05/12/counterfeit-medicines-in-wto-dispute-process-heating-up-at-
who/ (accessed on 13 March 2012).
16 Love, J. (2008), What is a Counterfeit?, Knowledge Ecology International 
(KEI): http://keionline.org/node/81 (accessed on 13 March 2012).
17 Love, ibid.
18 Matthews, D. and V. Munoz-Tellez (2007), ‘Parallel Trade: A User’s 
Guide’, in A. Krattiger, R.T. Mahoney, L. Nelson et al (eds) Intellectual Property 
Management in Health and Agriculture Innovation: A Handbook of Best Practices, 
Oxford, UK: MIHR and Davis, USA: PIPRA, pp. 1429–34.
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3. PATENT INFRINGEMENT
Patent infringement is not included in the definitions of counterfeiting 
used by the TRIPS Agreement or the WHO. Recently, however, the term 
counterfeiting has been used misleadingly to describe patent infringement, 
particularly in relation to generic medicines. A recent example of confu-
sion over this topic was the assertion that Switzerland was a major source 
of counterfeit medicines. According to Swiss officials, this actually referred 
to a case involving a dispute over alleged patent infringement, an area of 
much complexity and controversy, not usefully described as counterfeiting 
at all.19
In fact, patent infringement cases lie outside the scope of counterfeiting 
and are dealt with more appropriately by civil proceedings before national 
courts brought by the right holder.20
4. FALSIFIED MEDICINES
‘Falsified medicines’ is the term that can best distinguish sub-standard 
pharmaceutical products from counterfeits which contain the correct 
active ingredients but nonetheless violate trademark law. Falsified medi-
cines are a major threat to public health and safety. They may not possess 
any medicinal properties, may have insufficient active ingredients or may 
contain the wrong medicine. Suppliers of falsified medicines try to bypass 
the regulatory oversight by medicine licensing and supervisory authori-
ties. Such illegal trade often occurs through the Internet.21 Moreover, 
these products are channelled increasingly through the legal supply 
chain.22 These falsified medicines are part of the broader phenomenon of 
sub-standard pharmaceuticals that are manufactured below established 
standards of safety, quality and efficacy. They are usually deliberately 
and fraudulently mislabelled with respect to identity and/or source and 
19 Love, supra n. 16.
20 Matthews, D. (2008), The Fight against Counterfeiting and Piracy in the 
Bilateral Agreements of the EU, Brussels: Directorate General External Policies of 
the Union, European Parliament Briefing Paper.
21 European Medicines Agency (EMA), Falsified medicines: http://www.ema.
europa.eu/ema/index.jsp?curl=pages/special_topics/general/general_content_0 001 
86.jsp&mid=WC0b01ac058002d4e8&jsenabled=true (accessed 13 March 2012).
22 Directorate General Health and Consumers of the European Commission, 
Citizen’s Summary – Legal Proposal on Measures Preventing the Entry into the 
Legal Supply Chain of Medicinal Products which are Falsified in Relation to their 
Identity, History or Source.
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therefore also infringe trademarks and can additionally be considered 
counterfeit products because of this. These products may also include 
products with the correct ingredients but which are inserted in packaging 
which violates trademarks.23
Until recently, most of the falsified medicines circulating in developed 
countries were new, expensive lifestyle medicines, such as hormones, 
steroids and antihistamines. In developing countries the most common 
falsified medicines have been those used to treat life-threatening condi-
tions such as HIV/AIDS, tuberculosis and malaria. As the phenom-
enon spreads, more and more falsified medicines are becoming available, 
including anti-cancer drugs.24
Unlike counterfeit medicines which may contain the same active ingre-
dients as trademarked goods, however, falsified medicines contain the 
wrong or insufficient active ingredients. They can kill people and, as falsi-
fications become more sophisticated, the risk that falsified medicines reach 
patients increases. These falsified medicines can be unsafe, inefficient, or 
of low quality thus posing a risk to human health. Yet political wrangling 
over language and confusion over how to deal with the public health 
implications of this phenomenon is hampering international action.25 
Although countries unanimously recognize the threat posed by falsified 
medicines, many also believe that intellectual property rights enforcement 
concerns should not dominate the search for solutions.26
5.  THE WORLD HEALTH ORGANIZATION AND 
‘COUNTERFEIT MEDICINES’
Given that poor quality and sub-standard medicines can pose a major 
threat to public health, the WHO has endeavoured to promote the 
improvement of drug quality and safety. Historically, the WHO has 
focused its activities on strengthening the capacity of national drug regu-
latory authorities to identify and eradicate falsified medicines rather than 
promoting greater involvement of law enforcement agencies and the use 
of trademark or other intellectual property rights to address public health 
23 Ibid.
24 Ibid.
25 See also Clift, supra n. 2.
26 Saez, C. (2011), ‘WHO Members to Work to Disentangle Problem of Fake 
Medicines’, Intellectual Property Watch, 26 February: http://www.ip-watch.org/
weblog/2011/02/26/who-members-to-work-to-disentangle-problem-of-fake-medic i 
nes-ip-issues/ (accessed on 13 March 2012).
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concerns. The WHO has a clear mandate to improve ethical review and 
regulate the quality, safety and efficacy of health products and medical 
devices and, in 2008, this mandate was reinforced by World Health 
Assembly (WHA) adoption of a Global Strategy and Plan of Action on 
Public Health, Innovation and Intellectual Property.27
In addition to its other initiatives, since 2006 the WHO has also been 
sponsoring and acting as Secretariat to a new body called the International 
Medicinal Products Anti-Counterfeiting Taskforce (IMPACT), which in 
the past has been criticized for developing its own definition of counterfeit 
medicines that is not widely accepted by member countries in their national 
law.28 More recently, in 2010, IMPACT refined its terminology and refers 
to spurious/falsely-labelled/falsified/counterfeit (SFFC) medicines, which 
IMPACT defines as medicines that are deliberately and fraudulently 
mislabelled with respect to identity and/or source. This approach is more 
clearly in line with internationally-recognised definitions than the previous 
approach of IMPACT, which tended to speak exclusively of ‘counterfeit’ 
medicines.29
Until 2011, for instance, the IMPACT website itself noted that: ‘coun-
terfeit medical products are a major public health risk for all communities. 
The phenomenon has grown in recent years due to counterfeiting methods 
becoming more sophisticated and to the increasing amount of merchan-
dise crossing borders’. This statement has now been removed from the 
IMPACt site.
Since 2011, by adopting a broader conception of SFFC medicines, 
IMPACT seeks to coordinate efforts in order to protect public health 
against substandard and SFFC medical products.30 It works in partnership 
with major anti-counterfeiting organizations such as the World Customs 
Agency and INTERPOL.31 In addition, through informal networks 
of enforcement officers, IMPACT facilitates communication between 
enforcement and health authorities, seeks to improve international col-
laboration and develop appropriate mechanisms that will enable import-
27 World Health Assembly (2008), Global Strategy and Plan of Action on Public 
Health, Innovation and Intellectual Property, WHA61.21, 24 May: http://apps.who.
int/gb/ebwha/pdf_files/A61/A61_R21-en.pdf (accessed on 13 March 2012).
28 South Centre/CIEL, supra n. 1, p. 1.
29 World Health Organisation (2010) Medicines: spurious/falsely-labelled/
falsified/counterfeit (SFFC) medicines, Fact Sheet No. 275: http://www.who.int/
media centre/factsheets/fs275/en/index.html
30 International Medical Products Anti-Counterfeiting Taskforce – IMPACT: 
http://www.who.int/impact/en/ (accessed 10 April 2012)
31 Saez, supra n. 26.
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ing countries, especially in the developing world, to trigger investigation 
and identification of the actual source of SFFC medicines plaguing their 
markets.32
According to IMPACT in 2006, using its pre-SFFC terminology, coun-
terfeiting of medicines is greater in those regions where regulatory and 
legal oversight is weaker, and therefore:
●● most developed countries with effective regulatory systems and 
market control (eg USA, EU, Australia, Canada, Japan, New 
Zealand) currently have a very low proportion, ie less than 1 per cent 
of market value;
●● many developing countries in Africa, parts of Asia, and parts 
of Latin America have areas where more than 30 per cent of the 
medicines on sale can be counterfeit. Other developing countries, 
however, have less than 10 per cent overall, a reasonable estimate 
for all developing countries is therefore between 10 per cent and 30 
per cent;
●● many of the former Soviet republics have a proportion of counterfeit 
medicines which is above 20 per cent of market value – this falls into 
the developing country range. However other sources estimate that 
the real figure could be much higher;
●● medicines purchased over the Internet from sites that conceal their 
actual physical address are counterfeit in over 50 per cent of cases.33
In relation to specific countries, IMPACT has reported that:[bl]
●● the Russian Federal Service for Health Sphere Supervision (FSHSS) 
reported that 10 per cent of all drugs on the Russian market were 
counterfeit;
●● China’s research and development-based Pharmaceutical 
Association estimated that about 8 per cent of over-the-counter 
drugs sold in China were counterfeit.
Indian pharmaceutical companies have suggested that in India’s major 
cities, one in five strips of medicines sold is falsified. They claim a loss 
32 World Health Organization (2010), Medicines: spurious/falsely-labelled/
falsified/counterfeit (SFFC) medicines, Fact Sheet No. 275: http://www.who.int/
mediacentre/factsheets/fs275/en/index.html (accessed 13 March 2012)
33 IMPACT (2006), Counterfeit Medicines: an update on estimates: http://www.
who.int/medicines/services/counterfeit/impact/TheNewEstimatesCounterfeit.pdf 
(accessed 13 March 2012).
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in revenue of between 4 and 5 per cent annually. The industry also esti-
mates that spurious drugs have grown from 10 to 20 per cent of the total 
market.34
In order to provide guidance to WHO member countries on how 
best to draft national legislation to address concerns about counterfeit 
goods, on 12 December 2007 IMPACT adopted ‘Principles and Elements 
for National Legislation against Counterfeit Medical Products’.35 This 
document, prepared by the IMPACT Working Group on Legislative and 
Regulatory Infrastructure, raises a number of concerns, not least because 
the definition of counterfeit medicines contained in the document was 
incorporated without prior consultations with WHO member states, even 
though it amounted to a significant change of policy in that it redefined 
previous WHO guidelines on counterfeiting.
The IMPACT’s definition of counterfeit medicines states that:
A medical product is counterfeit when there is a false representation in relation 
to its identity,36 history or source.37 This applies to the product, its container 
or other packaging or labelling information. Counterfeiting can apply to both 
branded and generic products. Counterfeits may include products with correct 
ingredients/components,38 with wrong ingredients/components, without active 
ingredients, with incorrect amounts of active ingredients, or with fake packag-
ing. Quality defects or non-compliance with Good Manufacturing Practices/
Good Distribution Practices (GMP/GDP) in legitimate, authorized medical 
products should not be confused with counterfeiting.
The IMPACT definition significantly expanded the accepted WHO under-
standing of counterfeiting by replacing ‘deliberately and fraudulently’ with 
‘a false representation’, the latter which can occur irrespective of whether 
there was deliberate intent of any person or producer of goods. The effect 
was that even where there is no consumer deception, a medicine could 
still be considered as a counterfeit, with the burden of proof shifted away 
from enforcement officers to the producer or distributor of the counterfeit 
medicine. By incorporating the term ‘false representation’ the IMPACT 
34 Ibid.
35 IMPACT (2007), ‘Principles and Elements for National Legislation against 
Counterfeit Medical Products’, p. 3. Text endorsed by the IMPACT General 
Meeting, 12 December: http://www.who.int/impact/events/Final Principles for 
Legislation.pdf (accessed 13 March 2012).
36 IMPACT, ibid, p. 4: eg any misleading statement with respect to name, com-
position, strength, or other elements.
37 IMPACT, ibid, p. 4: eg any misleading statement with respect to manufac-
turer, country of manufacturing, country of origin, market authorization holder.
38 IMPACT, ibid, p. 4: This refers to ingredients or any other component of a 
medical product.
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definition also broadened the possibility of intellectual property infringe-
ments to include not only trademark violations but also infringement of 
a patent. Finally, one positive step taken by the IMPACT definition was 
that it stated that quality defects or non-compliance with GMP/GDP in 
legitimate, authorized medicinal products should not be confused with 
counterfeiting. This was welcome as a means to help ensure that legitimate 
parallel trade in grey market goods or generic products are not to be con-
sidered infringements of intellectual property rights.39
The IMPACT definition of counterfeiting was debated in the context 
of the WHO Intergovernmental Working Group on Public Health, 
Innovation and Intellectual Property (IGWG) during discussions on 
proposals to develop and strengthen legislative and regulatory oversight 
mechanisms and other measures against the production, trafficking and 
use of counterfeit medicines. However, WHO member states did not reach 
a consensus on including the IMPACT definition in the outcomes of the 
IGWG process and it was not included in the resulting WHA Global 
Strategy and Plan of Action for Public Health, Innovation and Intellectual 
Property in May 2008.40
It is also unclear how the work of IMPACT relates to the other activi-
ties of the WHO. Concerns about the work of IMPACT were raised at the 
WHA in May 2008 when a draft resolution on counterfeiting, sponsored 
by Gambia, Ghana, Nigeria, Tunisia, and United Arab Emirates, and 
later co-sponsored by the European Union,41 presented arguments that 
IMPACT initiatives were causing concern amongst WHO member states.42
On 11 May 2010, nearly 50 public health non-governmental organi-
zations (NGOs) also voiced concerns by sending an open letter to the 
Director General of the WHO, Margaret Chan, urging the WHO to find 
terminologies in the fight against dangerous medicines that are more 
public-health than intellectual-property oriented.43
Subsequently, the 63rd World Health Assembly on 21 May 2010 
established a new WHO working group on ‘substandard/spurious/falsely-
labelled/falsified/counterfeit’ medical products. The working group looked 
39 South Centre/CIEL, supra n. 1, p. 9.
40 World Health Assembly, supra n. 27.
41 A61/A/Conf. Paper No 1.
42 Third World Network (2008), IP: Counterfeit Issue Stirs Debate Among 
WHO Member States, SUNS No. 6536 12 August: http://www.twnside.org.sg/
title2/health.info/2008/twnhealthinfo20080802.htm (accessed 13 March 2012).
43 Third World Network (2010), NGO Open Letter Over WHO’s Involvement in 
‘Counterfeit Medicinal Products’ and in the IMPACT: http://www.twnside.org.sg/
title2/health.info/2010/health20100504.htm.
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again at IMPACT’s definition of counterfeit medicines in the context of its 
mandate to examine, from a public health perspective: the WHO’s role in 
measures to ensure availability of quality, safe, efficacious and affordable 
medical products; the WHO’s relationship with IMPACT; and the WHO’s 
role in the prevention and control of medical products of compromised 
quality, safety and efficacy such as substandard/spurious/falsely-labelled/
falsified/counterfeit medical products from a public health perspective, 
excluding trade and intellectual property considerations.44 As a result of 
this initiative, IMPACT revised its terminology and replaced references 
to counterfeit medicines with SFFC medicines in all its documentation 
post-2011.
6.  SEIZURES OF ‘COUNTERFEIT’ MEDICINES IN 
TRANSIT THROUGH THE EU
The international policy debate about the status of so-called ‘counter-
feit’ medicines and the free trade in generic pharmaceutical products 
that are legitimately made available on the market came to even greater 
prominence on 19 May 2010 when Brazil and India initiated consultations 
under the WTO dispute settlement procedure relating to the seizure of 
generic medicines considered as counterfeit products in the EU. The situ-
ation arose because EU Border Measures Regulation (BMR) 1383/2003 
concerning customs action against goods suspected of infringing certain 
intellectual property rights and the measures to be taken against goods 
found to have infringed such rights extends beyond counterfeit goods that 
infringe trademarks and includes the possibility that infringing acts can 
relate to patents and other intellectual property rights including copyright 
works, supplementary protection certificates, plant protection rights or 
geographical indications.45
The BMR permits customs authorities to seize all goods intended for 
44 O’Mara, K. (2010), ‘New Resolution Gives Governments Control Of WHO 
Work On False Medicines’, Intellectual Property Watch, 21 May 2010: http://
www.ip-watch.org/weblog/2010/05/21/new-resolution-gives-governments-control-
of-who-work-on-false-medicines/ (accessed 13 March 2012).
45 Article 2, paragraph 1(c) of Council Regulation (EC) No. 1383/2003 of 22 
July 2003 concerning customs action against goods suspected of infringing certain 
intellectual property rights and the measures to be taken against goods found to 
have infringed such rights, OJ L 196, 2 August 2003: http://eur-lex.europa.eu/
LexUriServ/LexUriServ.do?uri=CELEX:32003R1383:en:NOT (accessed on 13 
March 2012).
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import, export and re-export that are suspected of infringing intellectual 
property rights, even when an application has not been lodged by the 
right holder. This includes goods suspected of infringing a patent, with 
the effect that medicines can be seized by customs and listed in customs 
statistics under the broad heading of counterfeit and pirated goods. 
However, the determination of whether or not the medicinal products in 
question actually infringe a patent will depend on the national law of the 
member state when the alleged violation occurred and requires proceed-
ings to be initiated to this effect. This statistical reporting of medicinal 
products alleged to infringe a patent under the heading of counterfeit 
goods unhelpfully confuses disputes over patent infringement with coun-
terfeit medicines that infringe trademarks, as defined by the TRIPS 
Agreement and the WHO.46 This has heightened fears that the medi-
cines suspected of infringing patents are being confused with counterfeit 
medicines.
The concerns of Brazil and India involved several shipments of medi-
cines in transit from India to other developing countries that were 
detained en route through the EU on the grounds that they violated 
intellectual property rights, even though they were not destined for EU 
markets. At issue was the extent that the BMR can legitimately allow for 
goods suspected of patent infringement to be delayed and detained by 
customs authorities.
Acting under the terms of the BMR, since 2008 customs authorities in 
the Netherlands have seized, delayed and returned several shipments of 
generic medicines in transit through EU ports, en route to destinations in 
South America and Africa. They have done so on grounds of suspected 
patent infringement.47 The shipments in question have originated in the 
main from India and the intended final destination has generally been 
developing countries including Brazil, Colombia, Nigeria, Peru and 
Venezuela. The medicines at issue have been protected by patents in the 
EU but have not been subject to patents in the country of origin or the 
intended final destination. Based on complaints of alleged infringement 
by the owners of patents, Dutch customs authorities have seized a sub-
stantial number of consignments of generic medicinal products in transit 
through the Netherlands. These consignments have then been destroyed, 
returned to the country of origin or, in a few cases, permitted to proceed 
46 South Centre/CIEL, supra n. 1, p. 11.
47 Grosse Ruse-Khan, H. (2010), A Trade Agreement Creating Barriers to 
International Trade? Seizures of Generic Drugs in Transit and International IP 
Enforcement, Society of International Economic Law Online Proceedings Working 
Paper No. 2010/18, p. 3.
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to the country of destination. In all cases the Dutch authorities have acted 
pursuant to the BMR.48
While Brazil and India, together with other developing countries, have 
taken a strong stand against falsified medicines,49 they have taken an 
equally strong position in their complaints that the BMR conflates coun-
terfeiting of trademarked goods with broader issues of patent infringe-
ment disputes and goods that are legitimately in transit through the EU. 
On 12 May 2010 Brazil and India filed requests for consultations with the 
European Union and the Netherlands under the WTO dispute settlement 
process over the seizure of generic medicines in transit through the EU.50
According to Brazil and India’s requests for consultations, the EU and 
Dutch border measures were inconsistent with Article 1(1) of the TRIPS 
Agreement,51 together with various provisions of the border measures 
section (Articles 51–60) of the TRIPS Agreement. It has been argued 
that the alleged patent infringements by goods in transit do not result 
from a failure to meet the minimum standards of the TRIPS Agreement 
on intellectual property protection and enforcement and are therefore 
TRIPS-plus.52
The arguments presented by India were also instructive in that they 
made explicit the link between Article 28,53 read together with Article 2 
48 Ibid, p. 3.
49 See, for example, Gleicher, D. (2010), India, Brazil and South Africa Make 
a Stand on Falsified and Substandard Medicines, Global Health Europe, 21 
October: http://www.globalhealtheurope.org/index.php?option=com_content&
view=article&id=352:india-brazil-and-south-africa-make-a-stand-on-falsified-and- 
substandard-medicines&catid=60:your-opinion&Itemid=108 (accessed on 13 
March 2012).
50 Request for consultations by India: European Union and a Member State – 
Seizure of Generic Drugs (EU Seizure of Generics), WT/DS409/1, 19 May 2010; 
Request for consultations by Brazil: EC – Seizure of Generics, WT/DS409/1, 19 
May 2010.
51 Article 1.1 of the TRIPS Agreement (Nature and Scope of Obligations):
Members shall give effect to the provisions of this Agreement. Members may, 
but shall not be obliged to, implement in their law more extensive protection 
than is required by this Agreement, provided that such protection does not 
contravene the provisions of this Agreement. Members shall be free to deter-
mine the appropriate method of implementing the provisions of this Agreement 
within their own legal system and practice. 
52 Grosse Ruse-Khan, supra n. 47, p. 7.
53 Article 28 of the TRIPS Agreement (Rights Conferred):
1. A patent shall confer on its owner the following exclusive rights:
(a) where the subject matter of a patent is a product, to prevent third parties not 
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of the TRIPS Agreement,54 Article 4bis of the Paris Convention,55 and 
the last sentence of Article 6(i) of the WTO Decision of 30 August 2003 
on the implementation of paragraph 6 of the Doha Declaration on the 
TRIPS Agreement and Public Health.56 According to India, a cumulative 
having the owner’s consent from the acts of: making, using, offering for sale, 
selling, or importing for these purposes that product;
(b) where the subject matter of a patent is a process, to prevent third parties not 
having the owner’s consent from the act of using the process, and from the acts 
of: using, offering for sale, selling, or importing for these purposes at least the 
product obtained directly by that process.
2. Patent owners shall also have the right to assign, or transfer by succession, 
the patent and to conclude licensing contracts. 
54 Article 2 of the TRIPS Agreement (Intellectual Property Conventions): ‘1. 
In respect of Parts II, III and IV of this Agreement, Members shall comply with 
Articles 1 through 12, and Article 19, of the Paris Convention (1967).’
55 Article 4bis of the Paris Convention (Patents: Independence of Patents 
Obtained for the Same Invention in Different Countries):
1. Patents applied for in the various countries of the Union by nationals of 
countries of the Union shall be independent of patents obtained for the same 
invention in other countries, whether members of the Union or not.
2. The foregoing provision is to be understood in an unrestricted sense, in 
particular, in the sense that patents applied for during the period of priority 
are independent, both as regards the grounds for nullity and forfeiture, and as 
regards their normal duration.
3. The provision shall apply to all patents existing at the time when it comes 
into effect.
4. Similarly, it shall apply, in the case of the accession of new countries, to 
patents in existence on either side at the time of accession.
5. Patents obtained with the benefit of priority shall, in the various countries of 
the Union, have a duration equal to that which they would have, had they been 
applied for or granted without the benefit of priority. 
56 Article 6 of the Decision of the General Council of 30 August 2003 on 
Implementation of paragraph 6 of the Doha Declaration on the TRIPS Agreement 
and Public Health:
With a view to harnessing economies of scale for the purposes of enhancing 
purchasing power for, and facilitating the local production of, pharmaceutical 
products:
(i) where a developing or least-developed country WTO Member is a party 
to a regional trade agreement within the meaning of Article XXIV of the 
GATT 1994 and the Decision of 28 November 1979 on Differential and More 
Favourable Treatment Reciprocity and Fuller Participation of Developing 
Countries (L/4903), at least half of the current membership of which is made up 
of countries presently on the United Nations list of least developed countries, 
the obligation of that Member under Article  31(f) of the TRIPS Agreement 
shall be waived to the extent necessary to enable a pharmaceutical product 
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reading of these provisions confirms, inter alia, that the rights conferred 
on the owner of a patent cannot be extended to interfere with the freedom 
of transit of generic goods lawfully manufactured within, and exported 
from, India.
India further argued that Articles 41 and 42 of the TRIPS Agreement 
were at issue because the BMR had created barriers to legitimate trade, 
permitted the abuse of rights conferred on the owner of a patent, were 
unfair and inequitable, unnecessarily burdensome and complicated, and 
created unwarranted delays.57 Finally, India argued that Article 31 of the 
 produced or imported under a compulsory licence in that Member to be 
exported to the markets of those other developing or least developed country 
parties to the regional trade agreement that share the health problem in ques-
tion. It is understood that this will not prejudice the territorial nature of the 
patent rights in question; 
57 Article 41 of the TRIPS Agreement (Enforcement of intellectual property 
rights – General obligations):
1. Members shall ensure that enforcement procedures as specified in this Part 
are available under their law so as to permit effective action against any act of 
infringement of intellectual property rights covered by this Agreement, includ-
ing expeditious remedies to prevent infringements and remedies which consti-
tute a deterrent to further infringements. These procedures shall be applied in 
such a manner as to avoid the creation of barriers to legitimate trade and to 
provide for safeguards against their abuse.
2. Procedures concerning the enforcement of intellectual property rights shall 
be fair and equitable. They shall not be unnecessarily complicated or costly, or 
entail unreasonable time-limits or unwarranted delays.
3. Decisions on the merits of a case shall preferably be in writing and reasoned. 
They shall be made available at least to the parties to the proceeding without 
undue delay. Decisions on the merits of a case shall be based only on evidence 
in respect of which parties were offered the opportunity to be heard.
4. Parties to a proceeding shall have an opportunity for review by a judicial 
authority of final administrative decisions and, subject to jurisdictional provi-
sions in a Member’s law concerning the importance of a case, of at least the 
legal aspects of initial judicial decisions on the merits of a case. However, there 
shall be no obligation to provide an opportunity for review of acquittals in 
criminal cases.
5. It is understood that this Part does not create any obligation to put in place 
a judicial system for the enforcement of intellectual property rights distinct 
from that for the enforcement of law in general, nor does it affect the capacity 
of Members to enforce their law in general. Nothing in this Part creates any 
obligation with respect to the distribution of resources as between enforcement 
of intellectual property rights and the enforcement of law in general.
Article 42 of the TRIPS Agreement (Enforcement of Intellectual Property 
Rights – Fair and Equitable Procedures):
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TRIPS Agreement,58 read together with the WTO Decision of 30 August 
2003, was at issue because the EU Regulation authorized the interference 
with the freedom of transit of medicines that may be produced in, and 
exported from, India to WTO members with insufficient or no capacity 
in the pharmaceutical sector that seek to obtain supplies of such products 
needed to address their public health problems by making effective use of 
compulsory licensing.
On 28 July 2011, India announced an “Understanding” with the EU 
that puts more conditions on EU customs authorities before they can 
stop shipments of generic pharmaceuticals passing through Europe.59 The 
Understanding will ensure that the existence of a patent will not hinder 
Members shall make available to right holders civil judicial procedures con-
cerning the enforcement of any intellectual property right covered by this 
Agreement. Defendants shall have the right to written notice which is timely 
and contains sufficient detail, including the basis of the claims. Parties shall be 
allowed to be represented by independent legal counsel, and procedures shall 
not impose overly burdensome requirements concerning mandatory personal 
appearances. All parties to such procedures shall be duly entitled to substan-
tiate their claims and to present all relevant evidence. The procedure shall 
provide a means to identify and protect confidential information, unless this 
would be contrary to existing constitutional requirements. 
58 Article 31 (Other Use Without Authorization of the Right Holder):
Where the law of a Member allows for other use of the subject matter of a 
patent without the authorization of the right holder, including use by the gov-
ernment or third parties authorized by the government, the following provi-
sions shall be respected:
(a) authorization of such use shall be considered on its individual merits;
(b) such use may only be permitted if, prior to such use, the proposed user 
has made efforts to obtain authorization from the right holder on reasonable 
commercial terms and conditions and that such efforts have not been success-
ful within a reasonable period of time. This requirement may be waived by a 
Member in the case of a national emergency or other circumstances of extreme 
urgency or in cases of public non-commercial use. In situations of national 
emergency or other circumstances of extreme urgency, the right holder shall, 
nevertheless, be notified as soon as reasonably practicable. In the case of public 
non-commercial use, where the government or contractor, without making a 
patent search, knows or has demonstrable grounds to know that a valid patent 
is or will be used by or for the government, the right holder shall be informed 
promptly; 
59 Press Release (28 July 2011), Information Bureau, Government of India, 
Indian EU Reach an Understanding on Issue of Seizure of Indian Generic Drugs 
in Transit: http://pib.nic.in/newsite/erelease.aspx?relid=73554 (accessed 10 April 
2012)
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on passing generic shipments through the EU.60 A key element of the 
Understanding is the core principle that the mere fact that medicines are 
in transit through EU territory, and that there is a patent title applicable 
to such medicines in EU territory, does not in itself constitute enough 
grounds for customs authorities in any Member State to suspect that the 
medicines at stake infringe patent rights.61
7. CONCLUSION
By conflating issues of counterfeiting with patent infringement, the seizure 
of generic drugs by the Dutch customs authorities under the auspices 
of the BMR raises the prospect that public health imperatives are being 
jeopardized by a tendency to merge concerns about counterfeit goods 
that infringe trademarks, with the debate about how best to deal with 
medicines suspected of infringing patents. In fact, the most immediate 
concern for public health lies elsewhere with falsified medicines containing 
the wrong or insufficient active ingredients that may be a risk to human 
health. These are separate issues and should be treated as such.
Given the above discussion it is clear the diversity of meanings attrib-
uted to the term ‘counterfeit medicines’ highlights an urgent need for a 
universally-recognized definition that makes explicit the fact that only 
trademark violations can be considered acts of counterfeiting.62 Public 
health is not necessarily at risk from such counterfeit medicines. It is falsi-
fied medicines that are the real concern.
60 Baker, B.K. (2012) Settlement of India/EU WTO Dispute re Seizures of 
In-Transit Medicines: Why the Proposed EU Border. Regulation Isn’t Good Enough, 
PIJIP Research Paper No. 2012-02 American University Washington College of 
Law, Washington, D.C.
61 Intellectual Property Watch (2011), EU-India Agreement In WTO Dispute 
Raises Bar For EU Drug Seizures: http://www.ip-watch.org/2011/07/30/eu-india-
agreement-in-wto-dispute-raises-bar-for-eu-drug-seizures/ (accessed 10 April 
2012)
62 See also South Centre/CIEL, supra n. 1, p. 7. 
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